MX384236B - Productos farmaceuticos mejorados de peptido para resistencia a la insulina - Google Patents
Productos farmaceuticos mejorados de peptido para resistencia a la insulinaInfo
- Publication number
- MX384236B MX384236B MX2020000201A MX2020000201A MX384236B MX 384236 B MX384236 B MX 384236B MX 2020000201 A MX2020000201 A MX 2020000201A MX 2020000201 A MX2020000201 A MX 2020000201A MX 384236 B MX384236 B MX 384236B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin resistance
- improved peptide
- peptide pharmaceuticals
- pharmaceuticals
- modified peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004156P | 2014-05-28 | 2014-05-28 | |
| PCT/US2015/033042 WO2015184177A1 (en) | 2014-05-28 | 2015-05-28 | Improved peptide pharmaceuticals for insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX384236B true MX384236B (es) | 2025-03-14 |
Family
ID=54699825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000201A MX384236B (es) | 2014-05-28 | 2015-05-28 | Productos farmaceuticos mejorados de peptido para resistencia a la insulina |
| MX2016015594A MX371033B (es) | 2014-05-28 | 2015-05-28 | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015594A MX371033B (es) | 2014-05-28 | 2015-05-28 | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9856306B2 (enExample) |
| EP (2) | EP4397374A3 (enExample) |
| JP (4) | JP6697807B2 (enExample) |
| KR (3) | KR20250007694A (enExample) |
| CN (5) | CN117582516A (enExample) |
| AU (3) | AU2015266854B2 (enExample) |
| BR (1) | BR112016027595B1 (enExample) |
| CA (1) | CA2949701C (enExample) |
| DK (1) | DK3155017T3 (enExample) |
| ES (1) | ES2985732T3 (enExample) |
| FI (1) | FI3155017T3 (enExample) |
| HU (1) | HUE066179T2 (enExample) |
| IL (3) | IL285613B2 (enExample) |
| MX (2) | MX384236B (enExample) |
| NZ (2) | NZ757113A (enExample) |
| PL (1) | PL3155017T3 (enExample) |
| PT (1) | PT3155017T (enExample) |
| WO (1) | WO2015184177A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CA3134906A1 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| WO2014081872A1 (en) | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP2922877B1 (en) * | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN117582516A (zh) | 2014-05-28 | 2024-02-23 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US10905770B2 (en) | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| AU2019205905B2 (en) * | 2018-01-03 | 2024-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of NASH and other disorders |
| CA3168001A1 (en) * | 2020-02-21 | 2021-08-26 | Spitfire Pharma Llc | Glp-1r and gcgr agonists, formulations, and methods of use |
| MX2023006419A (es) * | 2020-12-02 | 2023-08-15 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Compuestos polipéptidos modificados con lactama. |
| MX2023006736A (es) * | 2020-12-07 | 2023-08-21 | Spitfire Pharma Llc | Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr. |
| CN117202924A (zh) * | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| CN113461747B (zh) * | 2021-07-12 | 2023-02-03 | 吉林化工学院 | 刺玫果中2个具有降血糖活性的化合物 |
| JP2026517987A (ja) * | 2023-05-24 | 2026-06-02 | ザ ユナイテッド バイオテクノロジー（ヘンチン）シーオー．，エルティーディー． | インスリン誘導体およびその使用 |
| TW202620036A (zh) | 2024-09-27 | 2026-05-16 | 美商卡默療法股份有限公司 | 肽酪胺酸－酪胺酸（ｐｙｙ）類似物及ｇｌｐ－１ｒ促效劑之組合療法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| EP2292273A3 (en) | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| US7776819B2 (en) | 2005-03-03 | 2010-08-17 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| CA2607566A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| RS51319B (sr) | 2005-09-22 | 2010-12-31 | Biocompatibles Uk Limited | GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| CA2728284C (en) * | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
| CA3134906A1 (en) * | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP4286400A3 (en) * | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| EP2922877B1 (en) | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| WO2014081872A1 (en) | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| BR112015025464A2 (pt) * | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| CN117582516A (zh) | 2014-05-28 | 2024-02-23 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| JP6581656B2 (ja) * | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | グルカゴンおよびｇｌｐ−１受容体のコアゴニスト |
| AU2019205905B2 (en) * | 2018-01-03 | 2024-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of NASH and other disorders |
-
2015
- 2015-05-28 CN CN202311098620.9A patent/CN117582516A/zh active Pending
- 2015-05-28 HU HUE15798956A patent/HUE066179T2/hu unknown
- 2015-05-28 PL PL15798956.7T patent/PL3155017T3/pl unknown
- 2015-05-28 CN CN201580041790.0A patent/CN106661097A/zh active Pending
- 2015-05-28 KR KR1020247042894A patent/KR20250007694A/ko active Pending
- 2015-05-28 CN CN202011222645.1A patent/CN113264994A/zh active Pending
- 2015-05-28 KR KR1020167036463A patent/KR102542164B1/ko active Active
- 2015-05-28 NZ NZ757113A patent/NZ757113A/en unknown
- 2015-05-28 MX MX2020000201A patent/MX384236B/es unknown
- 2015-05-28 PT PT157989567T patent/PT3155017T/pt unknown
- 2015-05-28 FI FIEP15798956.7T patent/FI3155017T3/fi active
- 2015-05-28 NZ NZ726623A patent/NZ726623A/en unknown
- 2015-05-28 EP EP24150928.0A patent/EP4397374A3/en active Pending
- 2015-05-28 CA CA2949701A patent/CA2949701C/en active Active
- 2015-05-28 AU AU2015266854A patent/AU2015266854B2/en active Active
- 2015-05-28 CN CN202311098595.4A patent/CN117180445A/zh active Pending
- 2015-05-28 DK DK15798956.7T patent/DK3155017T3/da active
- 2015-05-28 US US15/314,466 patent/US9856306B2/en active Active
- 2015-05-28 MX MX2016015594A patent/MX371033B/es active IP Right Grant
- 2015-05-28 ES ES15798956T patent/ES2985732T3/es active Active
- 2015-05-28 KR KR1020237018945A patent/KR20230084337A/ko not_active Ceased
- 2015-05-28 CN CN201910116865.7A patent/CN109865142A/zh active Pending
- 2015-05-28 WO PCT/US2015/033042 patent/WO2015184177A1/en not_active Ceased
- 2015-05-28 EP EP15798956.7A patent/EP3155017B1/en active Active
- 2015-05-28 IL IL285613A patent/IL285613B2/en unknown
- 2015-05-28 BR BR112016027595-0A patent/BR112016027595B1/pt active IP Right Grant
- 2015-05-28 JP JP2016569787A patent/JP6697807B2/ja active Active
-
2016
- 2016-11-17 IL IL249044A patent/IL249044B/en active IP Right Grant
-
2017
- 2017-11-21 US US15/820,127 patent/US10577405B2/en active Active
-
2020
- 2020-01-21 US US16/747,759 patent/US20200277351A1/en not_active Abandoned
- 2020-04-21 JP JP2020075470A patent/JP2020143066A/ja active Pending
- 2020-06-02 AU AU2020203609A patent/AU2020203609B2/en active Active
- 2020-06-21 IL IL275526A patent/IL275526B/en unknown
-
2022
- 2022-08-09 JP JP2022127266A patent/JP2022172128A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200659A patent/AU2023200659B2/en active Active
-
2024
- 2024-04-18 JP JP2024067692A patent/JP7858714B2/ja active Active
- 2024-11-11 US US18/943,440 patent/US20250136656A1/en active Pending
- 2024-12-19 US US18/988,066 patent/US20250313604A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360816B (es) | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. | |
| MX344219B (es) | Productos farmaceuticos peptidicos mejorados para resistencia a insulina. | |
| EP4397374A3 (en) | Improved peptide pharmaceuticals for insulin resistance | |
| WO2012158964A3 (en) | Improved peptide pharmaceuticals for osteoporosis | |
| CY1122803T1 (el) | Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων | |
| IL251462A0 (en) | Pharmaceutical formulations for oral administration of peptide or protein drugs | |
| BR112018072783A2 (pt) | proteínas de fusão elp para liberação controlada e retardada | |
| EP3200812A4 (en) | Novel 4 7 peptide monomer and dimer antagonists | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| IL261112A (en) | Conjugations of amino acid and peptide and conjugation process | |
| MX2024000004A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
| ZA201903657B (en) | Ras protein degradation inducing molecule and pharmaceutical composition | |
| SG11201705759SA (en) | Cytotoxic hexim1 peptides and uses thereof | |
| ZA202004658B (en) | Pharmaceutical composition comprising an apl type peptide | |
| IL252902A0 (en) | Amino acid and peptide conjugates and their uses | |
| EP3186272A4 (en) | Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same | |
| EP3257523A4 (en) | Use of polypeptide complex as polypeptide or protein drug carrier, method, and fusion protein complex thereof | |
| GB201705990D0 (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
| ZA201904386B (en) | S-arrestin peptides and therapeutic uses thereof | |
| EP3256578B8 (en) | Polypeptides for engineering integrase chimeric proteins and their use in gene therapy | |
| NZ746677A (en) | Novel alpha-1-microglobulin derived proteins and their use | |
| EP3345003A4 (en) | IDENTIFICATION OF PROTEINS IN THE ABSENCE OF PEPTIDE IDENTIFICATION | |
| IL271741A (en) | Peptide meters drug with improved pharmaceutical properties | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| AU2017305946A8 (en) | C1q and HMGB1 fusion proteins and uses thereof |